Cancer vaccines

POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, July 21, 2021

Isotopia has developed a unique, stable, and reliable GMP method to produce a highly pure form of n.c.a.

Key Points: 
  • Isotopia has developed a unique, stable, and reliable GMP method to produce a highly pure form of n.c.a.
  • Dr. Eli Shalom, CEO of Isotopia added, As Isotopia expands its manufacturing capabilities to secure supply for patients worldwide, we are always looking to partner with leaders in the radiopharmaceutical space and provide dependable support at all stages, clinical and commercial.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com .

Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Thursday, July 15, 2021

The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.

Key Points: 
  • The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
  • Our strong foundation of clinical data generated across both prostate cancer and non-small cell lung cancer suggest Lm-based immunotherapy may bring meaningful clinical benefit to patients and we look forward to continued momentum across the ADXS-HOT program.
  • The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.

Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).

Global $7.61 Billion Cancer Vaccines (Preventive, Therapeutic) Markets, 2015-2019, 2023F, 2025F, 2030F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021

Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.

Key Points: 
  • Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.
  • The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment.
  • The cancer vaccines market covered in this report is segmented by type into preventive cancer vaccines; therapeutic cancer vaccines.
  • It is also segmented by technology into dendritic cells (DC) cancer vaccines; recombinant cancer vaccines; antigen/adjuvant cancer vaccines; whole cell cancer vaccines; viral vector & DNA cancer vaccines, by cancer type into prostate; cervical; colorectal; throat; others and by end-user into cancer treatment centers; research institutes.

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

Retrieved on: 
Monday, June 28, 2021

The pipeline is described in Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy, which recently published in the Journal for Immunotherapy of Cancer.

Key Points: 
  • The pipeline is described in Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy, which recently published in the Journal for Immunotherapy of Cancer.
  • In clinical use, this neoepitope discovery system supports the targeted delivery of antigens with ImmunityBios second-generation Adeno platform.
  • The future of immunotherapy is in a personalized approach, said Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine - The Pfizer-BioNTech

Retrieved on: 
Monday, June 21, 2021

The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.

Key Points: 
  • The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.
  • According to Yale Medicine[2], they said that: (Pfizers vaccine has a) 95% efficacy in preventing COVID-19 in those without prior infection.
  • While the efficacy against infection varied between the two studies, both also showed the vaccine provides strong protection.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021

Retrieved on: 
Monday, June 21, 2021

The poster was also selected for inclusion in the Best of ILC summary, which highlights the most noteworthy scientific contributions at this years meeting.

Key Points: 
  • The poster was also selected for inclusion in the Best of ILC summary, which highlights the most noteworthy scientific contributions at this years meeting.
  • We are excited to share our preclinical data with the Hepatitis B medical community as we move our therapeutic vaccine candidate toward the clinic, said Aileen Rubio, PhD., Head of Research and Development for the company.
  • ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B.
  • The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B.

CaroGen Partners with BioCentriq™ for Clinical Production of its Novel Immunotherapy CARG-201

Retrieved on: 
Tuesday, June 22, 2021

BioCentriq is a New Jersey based full-service concept-to-clinic contract development manufacturing organization (CDMO) with a mission to support innovative companies reach clinical success.

Key Points: 
  • BioCentriq is a New Jersey based full-service concept-to-clinic contract development manufacturing organization (CDMO) with a mission to support innovative companies reach clinical success.
  • CaroGen is a private biotechnology company with a patented and transformative novel immunotherapy and vaccine platform called AVIDIO, or Artificial Virus for Infectious Diseases and Immuno-Oncology.
  • The AVIDIO platform technology was licensed from Yale University for worldwide use by CaroGen for both prophylactic and therapeutic vaccine applications.
  • CaroGen has completed preclinical proof-of-concept in HBV animal models and selected a clinical candidate, CARG-201.

Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC

Retrieved on: 
Monday, June 7, 2021

ELK CITY, Idaho, June 7, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today potent synergy between its tumor blood vessel targeting StemVacs-V iPSC immunotherapy and several classical tumor specific therapeutic vaccines.

Key Points: 
  • ELK CITY, Idaho, June 7, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today potent synergy between its tumor blood vessel targeting StemVacs-V iPSC immunotherapy and several classical tumor specific therapeutic vaccines.
  • Additionally, the experiments demonstrated killing tumor cells using conventional approaches such as chemotherapy, when performed together with StemVacs-V iPSC, led to the development of immunological memory towards the specific cancer.
  • It is believed that by starving the cancer of its blood supply, StemVacs-V iPSC may convert cold tumors to immunotherapy sensitive "hot tumors."
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

Retrieved on: 
Thursday, June 3, 2021

The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.

Key Points: 
  • The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.
  • The patient received a vaccine comprising of 30 tumor antigens including 27 cancer neoantigens and 3 shared antigens.
  • "We are encouraged by the interim data from our personalized cancer vaccine program showing tumor shrinkage in combination with anti-PD1.
  • At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment.